Expertise in
2
conditions

Christoph Tinchon

LKH Hochsteiermark, Standort Leoben
Leoben, AT 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
2
conditions
LKH Hochsteiermark, Standort Leoben
Leoben, AT 

Overview

Christoph Tinchon practices practicing medicine in Leoben, Austria.

Mr. Tinchon is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Chronic Myelomonocytic Leukemia (CMML), Breast Cancer, Febrile Neutropenia, Acute Myeloid Leukemia (AML), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 21 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

LKH Hochsteiermark, Standort Leoben
Leoben, Austria
Other Locations
St. Josef Spital
Vienna, Austria

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Austrian Myeloid Registry
Austrian Myeloid Registry
Enrollment Status: Recruiting
Publish Date: April 10, 2025
Intervention Type: Other
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Investigate the Efficacy and Safety of Dronabinol in the Improvement of ChemOthErapy-induced and Tumor-Related Symptoms in Patients With Locally Advanced or Metastatic Pancreatic Cancer During First-line Chemotherapy (DIsCOvER)
Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Investigate the Efficacy and Safety of Dronabinol in the Improvement of ChemOthErapy-induced and Tumor-Related Symptoms in Patients With Locally Advanced or Metastatic Pancreatic Cancer During First-line Chemotherapy (DIsCOvER)
Enrollment Status: Completed
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drug: Dronabinol
Study Phase: Phase 3
Isatuximab in Combination With Lenalidomide-Dexamethasone Compared to Lenalidomide-Dexamethasone in Elderly Patients (Aged ≥70 Years) With Newly Diagnosed Myeloma: a Randomized Phase II Study (SGZ-2019-12650)
Isatuximab in Combination With Lenalidomide-Dexamethasone Compared to Lenalidomide-Dexamethasone in Elderly Patients (Aged ≥70 Years) With Newly Diagnosed Myeloma: a Randomized Phase II Study (SGZ-2019-12650)
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drugs: Isatuximab-Irfc [Sarclisa], Lenalidomide, Dexamethasone Oral
Study Phase: Phase 2
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients- a Randomized, Placebo Controlled Phase II Trial DEFENCE (DEnosumab For the rEductioN of the Smoldering Myeloma transformatioN inCidence ratE)
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients- a Randomized, Placebo Controlled Phase II Trial DEFENCE (DEnosumab For the rEductioN of the Smoldering Myeloma transformatioN inCidence ratE)
Enrollment Status: Completed
Publish Date: February 11, 2025
Intervention Type: Drug
Study Drug: Denosumab
Study Phase: Phase 2
A Randomized Phase II, 2-armed Study in Transplant Ineligible (TI) Patients With Newly Diagnosed Multiple Myeloma (NDMM) Comparing Carfilzomib + Thalidomide + Dexamethasone (KTd) Versus Carfilzomib + Lenalidomide + Dexamethasone (KRd) Induction Therapy With Respect to Response Rates and Investigating a Carfilzomib (K) Monotherapy Maintenance Strategy
A Randomized Phase II, 2-armed Study in Transplant Ineligible (TI) Patients With Newly Diagnosed Multiple Myeloma (NDMM) Comparing Carfilzomib + Thalidomide + Dexamethasone (KTd) Versus Carfilzomib + Lenalidomide + Dexamethasone (KRd) Induction Therapy With Respect to Response Rates and Investigating a Carfilzomib (K) Monotherapy Maintenance Strategy
Enrollment Status: Completed
Publish Date: March 29, 2024
Intervention Type: Drug
Study Drugs: Carfilzomib, Thalidomide, Lenalidomide, Dexamethasone
Study Phase: Phase 2
View 5 Less Clinical Trials

21 Total Publications

Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma.
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma.
Journal: American journal of hematology
Published: August 25, 2023

Frequently Asked Questions about Christoph Tinchon

Is Christoph Tinchon a top-rated expert for Chronic Myelomonocytic Leukemia (CMML)?

MediFind is an objective health platform that identifies experts based on real-world data. Christoph Tinchon is classified as an Advanced expert for Chronic Myelomonocytic Leukemia (CMML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Christoph Tinchon participate in research or clinical trials?

Yes. Christoph Tinchon has published 21 articles and abstracts on conditions like Chronic Myelomonocytic Leukemia (CMML). You can view a list of Christoph Tinchon's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Tinchon's expertise for a condition
ConditionClose
      View All 15 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile